Lexaria Bioscience Corp. (LEXX)
LEXX Stock Price Chart
Explore Lexaria Bioscience Corp. interactive price chart. Choose custom timeframes to analyze LEXX price movements and trends.
LEXX Company Profile
Discover essential business fundamentals and corporate details for Lexaria Bioscience Corp. (LEXX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jan 2021
Employees
7.00
CEO
Richard C. Christopher
Description
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
LEXX Financial Timeline
Browse a chronological timeline of Lexaria Bioscience Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Nov 2026
EPS estimate is -$0.06.
Upcoming earnings on 28 Oct 2026
EPS estimate is -$0.06, while revenue estimate is $50.00k.
Earnings released on 13 Jul 2026
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%.
Earnings released on 13 Apr 2026
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $20.00k , missing expectations by -60.00%.
Earnings released on 13 Jan 2026
EPS came in at -$0.07 surpassing the estimated -$0.13 by +46.15%.
Earnings released on 26 Nov 2025
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $174.00k , beating expectations by +27.01%.
Earnings released on 14 Jul 2025
EPS came in at -$0.21 falling short of the estimated -$0.15 by -40.00%, while revenue for the quarter reached $174.00k , beating expectations by +27.01%.
Earnings released on 14 Apr 2025
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%, while revenue for the quarter reached $174.00k , beating expectations by +90.52%.
Earnings released on 10 Jan 2025
EPS came in at -$0.16 falling short of the estimated -$0.12 by -33.33%, while revenue for the quarter reached $183.92k , beating expectations by +83.92%.
Earnings released on 26 Nov 2024
EPS came in at -$0.15 falling short of the estimated -$0.11 by -36.36%, while revenue for the quarter reached $84.00k , missing expectations by -16.00%.
Earnings released on 12 Jul 2024
EPS came in at -$0.13 falling short of the estimated -$0.10 by -30.00%, while revenue for the quarter reached $84.00k , missing expectations by -44.00%.
Earnings released on 9 Apr 2024
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $145.00k .
Earnings released on 12 Jan 2024
EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%, while revenue for the quarter reached $151.28k .
Earnings released on 21 Nov 2023
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached -$3.43k .
Earnings released on 14 Jul 2023
EPS came in at -$0.37 falling short of the estimated -$0.25 by -48.00%, while revenue for the quarter reached $93.15k , missing expectations by -45.21%.
Earnings released on 14 Apr 2023
EPS came in at -$0.22 , while revenue for the quarter reached $20.03k , missing expectations by -89.46%.
Earnings released on 17 Jan 2023
EPS came in at -$0.30 , while revenue for the quarter reached $101.48k .
Earnings released on 25 Nov 2022
EPS came in at -$0.24 falling short of the estimated -$0.21 by -14.29%, while revenue for the quarter reached $111.15k , missing expectations by -43.00%.
Earnings released on 14 Jul 2022
EPS came in at -$0.41 falling short of the estimated -$0.28 by -46.43%, while revenue for the quarter reached $99.72k , missing expectations by -16.90%.
Earnings released on 11 Apr 2022
EPS came in at -$0.25 falling short of the estimated $0.21 by -219.05%, while revenue for the quarter reached $30.65k , missing expectations by -79.57%.
Earnings released on 14 Jan 2022
EPS came in at -$0.35 , while revenue for the quarter reached $13.88k .
Earnings released on 29 Nov 2021
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.35%, while revenue for the quarter reached $31.02k , beating expectations by +0.07%.
LEXX Stock Performance
Access detailed LEXX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
